LOS ANGELES, March 31, 2020 /PRNewswire/ — Aliant is offering a free 60-minute webinar on Thursday, April 2, 2020 from 9:00 AM-10:30 AM PST. This webinar will provide one-hour of California CLE credit. The program will feature a panel of leading attorneys in employment, corporate, real estate, bankruptcy, and asset protection. They will share their insight on the legal implications of COVID-19, and how businesses can minimize the financial damage. Some of the specific issues that will be addressed include:
About Aliant®
Aliant® is a cross-border transactional and litigation firm that delivers global capabilities with a strong local presence. Aliant attorney’s work together to deliver the best possible service, and this collaborative environment ensures our clients have ready access to expert advocacy in every country in which we have a presence. Our attorneys have the experience and connections necessary to be powerful advocates, litigators, and negotiators within our fields of expertise. From Europe, to Asia, to the Americas, and the Middle East, Aliant consistently provides a quality of service that is second to none. To learn more, visit www.aliantlaw.com
Contact:
Alysia Camp
Marketing Director
213-281-0069
236918@email4pr.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/aliant-announces-cle-webinar-on-covid-19-legal-issues-and-business-considerations-301032344.html
SOURCE Aliant
The New Year Introduces Continuum's Entry-Level Tier, Starting at $25,000 Per YearNEW YORK, Dec. 22,…
BOSTON, Dec. 22, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced its partnership with…
CHICAGO, Dec. 22, 2025 /PRNewswire/ -- TrustCommerce®, a Sphere company and leading provider of end-to-end…
MIAMI, Dec. 22, 2025 /PRNewswire/ -- BioFlorida, Inc. ("BioFlorida"), Florida's preeminent life sciences association, is…
Andreessen Horowitz leads the funding round which will accelerate the company's leadingtelehealth marketplaceAUSTIN, Texas, Dec.…
MMJ's position is further fortified by its FDA Orphan Drug Designations for the treatment of…